Why the study?
The authors aimed to investigate the expression pattern and clinical significance of MYL9 in glioblastoma.
Is MYL9 expression associated with prognosis in patients with glioblastoma?
Is MYL9 expression associated with prognosis in patients with glioblastoma?
MYL9 is a novel biomarker in glioblastoma, with high expression associated with poor prognosis and increased tumour aggressiveness.
High MYL9 may signal poorer GBM prognosis; leaves open its utility as a validated biomarker.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kruthika et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: